Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$1.96 USD
+0.01 (0.51%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.96 0.00 (0.00%) 6:50 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.96 USD
+0.01 (0.51%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.96 0.00 (0.00%) 6:50 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Zacks News
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
by Zacks Equity Research
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 251.9% in Syros Pharmaceuticals (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -12.50% and 4.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
by Zacks Equity Research
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.
Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
by Zacks Equity Research
Does Syros Pharmaceuticals, Inc. (SYRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 199.3% in Syros Pharmaceuticals, Inc. (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
by Zacks Equity Research
Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
KALA BIO (KALA) delivered earnings and revenue surprises of -58.60% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 4.08% and 0.06%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -17.12% and 10.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 11.11% and 13.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?